Findings from the ALINA study
Findings from the NRG Oncology/GOG Study 279
Wyost is highly similar to the reference product Xgeva which was authorised in the EU in 2011
Better risk counselling may be achieved using the mathematical model
Evidence for efficacy is based on the results from the DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 studies